Stent-based antirestenotic coatings (sirolimus/paclitaxel)

Catheter Cardiovasc Interv. 2002 Mar;55(3):404-8. doi: 10.1002/ccd.10034.
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents, Phytogenic / administration & dosage*
  • Antineoplastic Agents, Phytogenic / pharmacology
  • Cell Division / drug effects
  • Clinical Trials as Topic
  • Coated Materials, Biocompatible*
  • Coronary Restenosis / etiology
  • Coronary Restenosis / prevention & control*
  • Depression, Chemical
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Immunosuppressive Agents / pharmacology
  • Infusion Pumps, Implantable*
  • Muscle, Smooth, Vascular / cytology
  • Paclitaxel / administration & dosage*
  • Paclitaxel / pharmacology
  • Sirolimus / administration & dosage*
  • Sirolimus / pharmacology
  • Stents* / adverse effects

Substances

  • Antineoplastic Agents, Phytogenic
  • Coated Materials, Biocompatible
  • Immunosuppressive Agents
  • Paclitaxel
  • Sirolimus